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A B S T R A C T
Background
This is an update of a review first published in 2003 and updated in 2012.
Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment
of refractory cancer pain, when opioids alone or in combination with appropriate adjuvant analgesics prove to be ineffective. Ketamine
is known to have psychomimetic (including hallucinogenic), urological, and hepatic adverse effects.
Objectives
To determine the effectiveness and adverse effects of ketamine as an adjuvant to opioids for refractory cancer pain in adults.
Search methods
For this update, we searched MEDLINE (OVID) to December 2016. We searched CENTRAL (CRSO), Embase (OVID) and two
clinical trial registries to January 2017.
Selection criteria
The intervention considered by this review was the addition of ketamine, given by any route of administration, in any dose, to pre-
existing opioid treatment given by any route and in any dose, compared with placebo or active control. We included studies with a
group size of at least 10 participants who completed the trial.
Data collection and analysis
Two review authors independently assessed the search results and performed ’Risk of bias’ assessments. We aimed to extract data on
patient-reported pain intensity, total opioid consumption over the study period; use of rescue medication; adverse events; measures of
patient satisfaction/preference; function; and distress. We also assessed participant withdrawal (dropout) from trial. We assessed the
quality of the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation).
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Main results
One new study (185 participants) was identified by the updated search and included in the review. We included a total of three studies
in this update.
Two small studies, both with cross-over design, with 20 and 10 participants respectively, were eligible for inclusion in the original review.
One study with 20 participants examined the addition of intrathecal ketamine to intrathecal morphine, compared with intrathecal
morphine alone. The second study with 10 participants examined the addition of intravenous ketamine bolus in two different doses
to ongoing morphine therapy, compared with placebo. Both of these studies reported reduction in pain intensity and reduction in
morphine requirements when ketamine was added to opioid for refractory cancer pain. The new study identified by the updated search
had a parallel group design and 185 participants. This placebo-controlled study examined rapid titration of subcutaneous ketamine to
high dose (500 mg) in participants who were using different opioids. There were no differences between groups for patient-reported
pain intensity.
Pooling of the data from the three included trials was not appropriate because of clinical heterogeneity.
The study examining intrathecal drug administration reported no adverse events related to ketamine. In the study using intravenous
bolus administration, ketamine caused hallucinations in four of 10 participants. In the rapid dose escalation/high-dose subcutaneous
ketamine study, there was almost twice the incidence of adverse events in the ketamine group, compared to the placebo group, with
the most common adverse events being needle site irritation and cognitive disturbance. Two serious adverse events (bradyarrhythmia
and cardiac arrest) thought to be related to ketamine were also reported in this trial.
For all three studies there was an unclear risk of bias overall. Using GRADE, we judged the quality of the evidence to be very low due
to study limitations and imprecision due to the small number of participants in all comparisons.
Authors’ conclusions
Current evidence is insufficient to assess the benefits and harms of ketamine as an adjuvant to opioids for the relief of refractory cancer
pain. The evidence was of very low quality, meaning that it does not provide a reliable indication of the likely effect, and the likelihood
that the effect will be substantially different is high. Rapid dose escalation of ketamine to high dose (500 mg) does not appear to have
clinical benefit and may be associated with serious adverse events. More randomised controlled trials (RCTs) examining specific low-
dose ketamine clinical regimens in current use are needed.
P L A I N L A N G U A G E S U M M A R Y
Adding ketamine to opioid for opioid-resistant cancer pain
Bottom line
The benefits and harms of adding low-dose ketamine to strong pain-killers such as morphine for the relief of cancer pain are not yet
established. High-dose ketamine does not appear to be effective and may be associated with serious side effects.
Background
This review is an update of a review first published in 2003 and updated in 2012.
Morphine-like drugs (opioids) are frequently prescribed for moderate and severe cancer pain, but in some cases these drugs are not
effective. Ketamine, an anaesthetic agent, is used in low doses in palliative care to improve analgesia when opioids alone are ineffective.
Study characteristics
In December 2016 and January 2017, we searched for clinical trials on the addition of ketamine to morphine-like drugs for cancer
pain.
We found one new study, together with the two studies included in the original review. The three studies were very different, using
different doses of ketamine, different routes of administration and different durations of treatment and it was not possible to combine
the results of these studies.
Key results
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The two smallest studies reported that the addition of ketamine to morphine reduced pain intensity and morphine requirements. The
third study which used high doses of ketamine reported no clinical benefit of adding ketamine to different opioids. Increased doses of
ketamine in some participants caused side effects such as hallucinations. The study which examined high doses of ketamine reported
two serious adverse events, which may have been related to ketamine. Although two out of three studies reported reduction in pain,
this could be due to chance in such small studies.
Quality of the evidence
We rated the quality of the evidence using four levels: very low, low, moderate, or high. Very low-quality evidence means that we are
very uncertain about the results. High-quality evidence means that we are very confident in the results. The evidence from the studies
was of very low quality. There were problems with the design of some studies and there were not enough data to answer some parts of
our review question.
B A C K G R O U N D
This is an update of a previously published review in the Cochrane
Database of Systematic Reviews (2003, Issue 1 (Bell 2003)), and
updated in 2012 (Bell 2012b) on ketamine as an adjuvant to
opioids for cancer pain.
Description of the condition
Studies report that moderate to severe pain is common in pa-
tients with advanced cancer (Are 2017). Cancer pain that is re-
fractory to standard treatment occurs in 10% to 20% of these pa-
tients (Afsharimani 2015). Cancer pain is often of mixed aetiology
and may have nociceptive, neuropathic and inflammatory com-
ponents. Neuropathic pain which results from tumour infiltration
in nerve plexi and damage of nerve tissue can be especially difficult
to treat (Fallon 2013). Opioids (for example, morphine, fentanyl,
hydromorphone, oxycodone, codeine) are frequently prescribed
for the relief of moderate and severe cancer pain. However, not all
cancer pain is sufficiently relieved by opioids alone.
Description of the intervention
The usual indication for using ketamine as an adjuvant to opi-
oid in cancer pain is for pain which is unresponsive to opioids
and adjuvant analgesics, for example in the case of refractory neu-
ropathic pain or opioid tolerance. Clinical reports indicate that,
when added to opioids, low subanaesthetic doses of ketamine may
give improved analgesia (Sosnowski 1993; Fine 1999; Bell 1999).
The practice of using ketamine as an adjuvant to opioids in the
treatment of cancer pain that does not respond to opioids alone,
or to opioids in combination with adjuvant analgesic drugs, is
discussed in several pain and palliative care textbooks (Stannard
2005; Twycross 2009; Cherny 2015). Ketamine is not licensed for
this purpose and this is an update of the first systematic review
undertaken to establish the evidence base for this practice.
Ketamine hydrochloride has been used as a general anaesthetic
agent for over 30 years, and is commonly given intravenously
or intramuscularly for surgical anaesthesia (Fisher 2000). Ke-
tamine causes dissociative anaesthesia and also has analgesic effects
(Grahame-Smith 2002); because it increases sympathetic nervous
system activity, it is a useful anaesthetic for high-risk patients who
require a high degree of sympathetic activity to maintain cardio-
vascular function. However, the benefits are tempered by the high
incidence of hallucinations and other transient psychomimetic
sequelae when ketamine is used for anaesthesia in adults (BNF
2012). More recently, urological toxicity and hepatic toxicity have
been described as adverse effects of ketamine (Bell 2012a).
In the 1980s ketamine was discovered to have N-methyl-D-aspar-
tate (NMDA) receptor antagonist properties and acts by block-
ing excitatory glutamate receptors in the central nervous system.
There is an association between nociceptive activity involving the
NMDA receptor and hyperalgesia/allodynia, and reduced opioid
sensitivity (Dickenson 1994). The NMDA receptor plays a role
in the development of opioid tolerance (Trujillo 1991;Mao 1995;
Mayer 1995). Currently, there is much focus on ketamine for the
treatment of major depression. A recent paper reports that ke-
tamine metabolites exert antidepressant actions independent of
NMDA receptor inhibition (Zanos 2016).
Evidence from experimental animal models, human volunteer
studies and small clinical trials indicates that subanaesthetic doses
of ketamine alleviate various chronic and neuropathic pain syn-
dromes (Fisher 2000).Ketamine has anti-inflammatory effects and
may have an effect in inflammatory pain (Dale 2012; Sawynok
2014). However, the clinical use of ketamine at subanaesthetic
dose levels has also been restricted by unpleasant adverse effects,
typically sedation, nausea, disagreeable psychological disturbances
or hallucinations (Willetts 1990).
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Racemic ketamine is a mixture of two stereoisomers: R(-) and
S(+). More recently, S-ketamine has been introduced. S(+) ke-
tamine produces longer hypnosis than the (-) isomer, and causes
a greater rise in blood pressure and heart rate, less locomotor ac-
tivity, and a shorter recovery time, and it is postulated to have
twice the analgesic efficacy of racemic ketamine. S(+) ketamine is
also thought to have a safer adverse effect profile (Grahame-Smith
2002). The majority of published clinical studies in postopera-
tive and chronic pain have used racemic ketamine. For a review
on the pharmacokinetics of ketamine see Peltoniemi 2016. The
oral bioavailability of ketamine is low and the drug undergoes fast
cytochrome P450 (CYP) mediated N-demethylation to norke-
tamine. Approximately 80% of ketamine undergoes N-demethy-
lation tonorketamine byCYP3A andCYP2B6 enzymes (Kharasch
1992; Yanagihara 2001;Hijazi 2002), with a smaller amount being
metabolised to 4-and 6-hydroxyketamines (Woolf 1987). Com-
pared to ketamine, norketamine is an approximately three to five
times weaker NMDA receptor antagonist (Leung 1986; Ebert
1997). Beingmetabolised byCYP3A enzymes, ketaminemay have
significant interactions with opioids and other drugs. Studies in
rodents indicate important interactions between ketamine and
opioids. Edwards 2002 reported that in mice, distribution of ke-
tamine into the brain was increased by low plasma concentrations
of alfentanil. Recently Lilius 2015 found that ketamine co-ad-
ministration attenuates morphine tolerance and leads to increased
brain concentrations of both drugs in the rat.
Ketamine has multiple routes of administration and is commonly
given as an adjuvant to pre-existing opioid treatment. A number of
systematic reviews report that ketamine is effective in acute post-
operative pain and reduces morphine requirements (Bell 2006;
Laskowski 2011; Assouline 2016).
How the intervention might work
By blocking activity at the NMDA receptor, ketamine may re-
duce neuropathic-related cancer pain. Blocking NMDA receptor
activity may reduce opioid tolerance thus increasing/restoring the
analgesic effect of opioid. Ketamine has anti-inflammatory effects
and may be beneficial in inflammatory cancer pain.
Why it is important to do this review
This is an update of a Cochrane review first published in 2003,
and previously updated in 2012. Ketamine is routinely used in the
palliative care setting for the treatment of refractory cancer pain.
Earlier versions of this review found limited and heterogenous
data, and there was insufficient evidence to be able to make any
conclusions. In recent years the standards used to assess evidence
in pain trials have changed substantially, for example there is now
particular attention being paid to participant withdrawal from
trials, and statistical imputation following withdrawal, which can
substantially alter estimates of efficacy. Themost important change
is the move from using average pain scores, or average change in
pain scores, to the number of people who have a large decrease
in pain (by at least 50%) (PaPaS 2012). This update assesses the
current evidence using the new criteria for what constitutes reliable
evidence in pain trials.
O B J E C T I V E S
To determine the effectiveness and adverse effects of ketamine as
an adjuvant to opioids for refractory cancer pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs)
• Double-blind studies
• Placebo- or active-controlled trials, both with or without
cross-over, in in-patient and out-patient settings
We excluded studies with a group size of fewer than 10 participants
who completed the study.
Types of participants
The population addressed by the review included adult patients
(aged 18 or over) with cancer and pain despite being currently
treated by an opioid agonist (e.g. morphine, fentanyl, oxycodone),
in any dose and by any route. We excluded studies including pa-
tients who were on an established NMDA-receptor antagonist
treatment before the study began. We did not consider volunteer
studies.
Types of interventions
The intervention considered by this review was the addition of
ketamine, given by any route of administration, in any dose, to
pre-existing opioid treatment given by any route and in any dose.
Types of outcome measures
Primary outcomes
The primary outcomemeasure was patient-reported pain intensity
(e.g. visual analogue scales (VAS) and verbal rating scales).
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Secondary outcomes
Secondary outcome measures were:
• total opioid consumption over the study period;
• rescue medication;
• adverse events;
• measures of patient satisfaction/ preference;
• function;
• distress.
Search methods for identification of studies
Electronic searches
We searched the following databases for this update:
• CENTRAL (CRSO) April 2012 to January 2017;
• MEDLINE (OVID) May 2012 to December 2016;
• Embase (OVID) May 2012 to 2017 week 1.
Please see Appendix 1 and Appendix 2 for the searches con-
ducted for the original review in 2003. For the searches conducted
for the update in 2012 please see Appendix 3, Appendix 4 and
Appendix 5. For searches conducted for the current update please
see Appendix 6.
Searching other resources
We
also searched two clinical trial registers (https://clinicaltrials.gov/)
and the World Health Organization (WHO) International Clin-
ical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/)
to identify additional published or unpublished data.
Language
We did not restrict searches or inclusion by language.
Data collection and analysis
Selection of studies
Two review authors (RB and EK) independently assessed the titles
and abstracts from each of the electronic databases searched for
relevance.We retrieved potentially relevant trial reports in full and
three review authors (RB, CE, EK) assessed them for inclusion in
the review.
Data extraction and management
Wedesigned a data extraction form, and two review authors (RFB,
EK) independently collected the following data items if available.
• Publication details.
• Patient population, number of participants, age, condition.
• Description of the intervention(s) and control.
• Outcomes: pain intensity, total opioid consumption, rescue
medication, measures of patient satisfaction/preference, distress
and function.
• Adverse events (major and minor).
• Quality (evaluated using the Oxford Quality Scale (Jadad
1996)).
• Validity (evaluated using the Oxford Pain Validity Scale
(OPVS) (Smith 2000)).
This information is recorded in the ’Characteristics of included
studies’ table.
Assessment of risk of bias in included studies
Two review authors (RFB, EK) independently assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
and adapted from those used by the Cochrane Pregnancy and
Childbirth Group, with any disagreements resolved by discussion
with a third author (CE).We completed ’Risk of bias’ table for each
included study using the ’Risk of bias’ tool in RevMan (RevMan
2014).
We assessed the following for each included study.
• Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated). We excluded studies using a non-
random process (e.g. odd or even date of birth; hospital or clinic
record number).
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes); unclear risk
of bias (method not clearly stated). We excluded studies that did
not conceal allocation (e.g. open list).
• Blinding of participants and personnel (checking for
possible performance bias). We assessed the methods used to
blind study participants and personnel from knowledge of which
intervention a participant received. We assessed methods as: low
risk of bias (study states that it was blinded and describes the
method used to achieve blinding, such as identical tablets
matched in appearance and smell, or a double-dummy
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technique); unclear risk of bias (study states that it was blinded
but does not provide an adequate description of how it was
achieved).
• Blinding of outcome assessment (checking for possible
detection bias). We assessed the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed the methods as:
low risk of bias (study has a clear statement that outcome
assessors were unaware of treatment allocation, and ideally
describes how this was achieved); unclear risk of bias (study states
that outcome assessors were blind to treatment allocation but
lacks a clear statement on how it was achieved).
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk (< 10% of participants did not
complete the study or used ‘baseline observation carried forward’
analysis, or both); unclear risk of bias (used ’last observation
carried forward’ analysis); high risk of bias (used ’completer’
analysis).
• Selective reporting (reporting bias). We assessed the risk of
reporting bias as: low risk of bias (all intended outcomes
reported); unclear risk of bias (any anomaly in reporting, such as
participants contributing more than one set of data, or some
outcomes not participant-reported); high risk of bias
(prespecified outcome of interest not reported).
• Size of study (checking for possible biases confounded by
small size). We assessed studies as being at low risk of bias (≥
200 participants per treatment arm); unclear risk of bias (50 to
199 participants per treatment arm); high risk of bias (< 50
participants per treatment arm).
Measures of treatment effect
For dichotomous outcomes we planned to calculate the risk ratio
(RR) and the corresponding 95% confidence interval (CI) and P
value. We planned to calculate the number needed to treat for an
additional beneficial outcome (NNTB)/number needed to treat
for an additional harmful outcome (NNTH) as the reciprocal of
the absolute risk difference (McQuay 1998). For continuous out-
comes, we planned to calculate the mean difference (MD) and its
corresponding 95% CI whenmeans and standard deviations (SD)
were available. If such information was unavailable we planned to
use the methods described in Chapter 16 of the Cochrane Hand-
book for Systematic Reviews of Interventions to calculate standardised
mean differences (SMD), from for example, F ratios, t values, Chi2
values and correlation coefficients (Higgins 2011). In cases where
continuous measures were used to assess the same outcomes using
different scales, we would have pooled these data using Hedges’ g
to estimate the SMD. When effect sizes could not be pooled, we
planned to report study level effects narratively.
Unit of analysis issues
We only included studies that randomised the individual partici-
pant.
Dealing with missing data
We assessed missing data in the included studies. Where possible,
we investigated and reported the reasons and numbers of those
dropping out of each included study. For dichotomous outcomes,
we planned to perform an intention-to-treat (ITT) analysis. If
there was missing participant information, we recorded this and
commented in the individual study’s ’Risk of bias’ table. Partici-
pants with missing data would be assigned to a ’zero improvement
category’.
We paid particular attention to methods used for imputation of
missing data due to withdrawals for adverse events and lack of
efficacy. Where data were missing for substantial numbers of par-
ticipants (greater than 10%), we would have rated the study as
high risk of bias.
Assessment of heterogeneity
We planned to deal with clinical heterogeneity by combining
studies that examined similar conditions. Statistical heterogeneity
would have been assessed visually (L’Abbé 1987).
Assessment of reporting biases
We looked for the original trial protocols of the included studies
and compared the results to these when theywere found.Whenno
protocol was available, we compared the reported outcomes against
the Methods section of the paper to look for selective reporting of
outcomes.
We planned to assess publication bias using a method designed to
detect the amount of unpublished data with a null effect required
to make any result for pain clinically irrelevant (usually taken to
mean an NNTB of 10 or higher) (Moore 2008). In the event,
there were insufficient data for statistical analysis.
Data synthesis
Quality of the evidence
We planned to combine data in a series of meta-analyses on both
primary and secondary outcomes.
We used the GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) system to rank the quality of the
evidence using the GRADE profiler Guideline Development Tool
software (GRADEpro GDT 2015), and the guidelines provided
in Chapter 12.2 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
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TheGRADE approach uses five considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of the body of evidence for each outcome.
The GRADE system uses the following criteria for assigning grade
of evidence:
• high: we are very confident that the true effect lies close to
that of the estimate of the effect;
• moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different;
• low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect;
• very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We decreased the grade rating by one (- 1) or two (- 2) if we
identified:
• serious (- 1) or very serious (- 2) limitation to study quality;
• important inconsistency (- 1);
• some (- 1) or major (- 2) uncertainty about directness;
• serious (-1) or very serious (-2) imprecise or sparse data;
• high probability of reporting bias (- 1).
’Summary of findings’ table
We planned to include a ’Summary of findings’ table as set out
in the PaPaS author guide PaPaS 2012 and recommended in the
Cochrane Handbook (Chapter 11, Higgins 2011) to present the
main findings in a transparent and simple tabular format. How-
ever, we judged that a ’Summary of findings’ table with only three
very different studies would be unhelpful.
Subgroup analysis and investigation of heterogeneity
We did not plan subgroup analyses.
Sensitivity analysis
Had there been sufficient data available, we would have examined
the robustness of meta-analyses by conducting a sensitivity analy-
sis.
R E S U L T S
Description of studies
The original review included one study which compared intrathe-
cal ketamine + intrathecal morphine with intrathecal morphine
alone (Yang 1996), and one study which compared intravenous
ketamine bolus with intravenous bolus of placebo as a supplement
to ongoing morphine therapy (Mercadante 2000). We found one
new study for this update which compared subcutaneous infusion
of ketamine at three dose levels (100 mg, 300 mg, or 500 mg)
with placebo in participants with ongoing treatment with opioids
(Hardy 2012).
Results of the search
The updated searches of the three databases (see Electronic
searches) retrieved 271 records. Our searches of the trials registers
did not identify further studies. Our screening of the reference
lists of the included publications did not reveal additional RCTs.
We therefore had a total of 271 records.
Once duplicates had been removed, we had a total of 216 records.
We excluded215 records based on titles and abstracts.We obtained
the full text of the remaining record and this study was included
(Hardy 2012). For a further description of our screening process,
see the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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We identified three ongoing studies and added these records to
Characteristics of studies awaiting classification. Two additional
trials with status ’completed’ do not appear to have been published
and possibly represent double registration of the same trial. These
are described under Characteristics of ongoing studies.
Protocols for the studies by Yang 1996 and Mercadante 2000
were not available. The protocol for the study by Hardy 2012 was
retrieved.
Included studies
Study design
Two included studies (Yang 1996; Mercadante 2000) had a cross-
over design. The trial conducted in Taiwan by Yang 1996 com-
pared ketamine and morphine with morphine alone. The time
period over which the intervention was assessed was not stated
in the trial report, but there is an implication that the study was
conducted over a period of days. (Attempts to contact the author
to confirm the trial duration were not successful). The trial con-
ducted in Italy byMercadante 2000 was a placebo-controlled trial
and was conducted over a three-hour period. The most recent trial
Hardy 2012 was a multisite, dose-escalation, double-blind, ran-
domised, placebo-controlled parallel group study with a duration
of five days.
Study population
Yang 1996: Twenty hospitalised participants (10 men and 10
women) aged 22 to 69 years with cancer pain of variable sever-
ity treated with opioids. The primary cancer sites were stomach,
cervix, liver, lung, colon, pancreas.
Mercadante 2000: Ten participants (sevenmen and three women)
aged 21 to 69 years who had pain unrelieved by their dose of
morphine, and a Karnofsky status of 50 or more. The primary
cancer sites were: bladder, rectum, lung, histiocytoma and uterus.
In this study, the pain was classified as being “neuropathic” or
having a “neuropathic component”.
Hardy 2012: Hospitalised palliative care participants aged 18 or
older, with refractory chronic nociceptive or neuropathic pain sec-
ondary to cancer or its treatment (Brief Pain Inventory (BPI) av-
erage pain score ≥ 3 despite ongoing treatment with opioids and
co-analgesics at predefined dose levels). One hundred and eighty
participants were randomly assigned, two were deleted from the
analysis, 93 were allocated to ketamine and 92 to placebo. Ninety-
one received ketamine and 90 received placebo. One hundred and
forty-nine were defined as having completed the trial, although
only 39 participants in the ketamine arm and 35 participants in
the placebo arm received either ketamine or placebo for the full
five-day period.
Intervention
Yang 1996 assessed intrathecal ketamine 1.0 mg twice daily as ad-
juvant to intrathecal morphine, compared with intrathecal mor-
phine alone. The morphine dose was titrated until participants’
pain relief had been stable for 48 hours, then the participants
were randomly crossed over (no washout period) tomorphine plus
ketamine or continued on morphine (control), administered in-
trathecally twice a day.
Mercadante 2000 assessed two doses of ketamine (0.25 mg/kg and
0.5 mg/kg) administered intravenously as a bolus as adjuvant to
ongoing morphine therapy, compared with saline. Patients were
randomly assigned to receive in turn either 0.25 mg/kg or 0.5 mg/
kg ketamine or saline, with a two-day washout period between
each intervention/control.
Hardy 2012 assessed either placebo (normal saline) or ketamine at
three dose levels (100 mg, 300 mg, or 500 mg) as a subcutaneous
infusion in a five-day schedule, starting at the first dose level (100
mg/24 hours), as a supplement to ongoing opioid therapy. If 80%
of the study drug had been delivered, and average pain improved
by ≥ 2 BPI units, with no more than four doses of breakthrough
medication, the dose remained the same. If not, the dose was
increased to the next level.
Morphine was the only opioid participants received in the studies
by Yang 1996 and Mercadante 2000. The route of administration
of morphine in the study by Yang 1996 was intrathecal, while
morphine was given by varied routes of administration (oral, in-
travenous or subcutaneous) in the trial by Mercadante 2000. The
opioid was not standardised in the study by Hardy 2012 where
participants used different opioids (morphine, oxycodone, hydro-
morphone, methadone, fentanyl, sufentanil, alfentanil) given by
different routes of administration (oral, transdermal or parenteral).
It is assumed that racemic ketamine was used in all three studies.
Rescue medication
Yang 1996: In this trial a rescue dose of 5 mg morphine was
administered intramuscularly as needed. Mercadante 2000 does
not report the use of rescue medication. Hardy 2012 states that
the participants had access to breakthrough analgesia and record
the number of doses, but do not describe the rescue medication.
Outcomes
Yang 1996 measured patient-reported pain intensity (zero to 10
numerical, 10 worst pain imaginable); pain frequency (four-point
verbal ordinal scale), group morphine dose, total titrated intrathe-
cal morphine, total rescue medication, frequency of intrathecal
titration. Mercadante 2000 measured patient-reported pain inten-
sity (zero to 10 numerical scale) at 30-, 60-, 90-, 120-, and 180-
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minute intervals; and adverse events. Hardy 2012 defined the pri-
mary outcome as a positive response defined as a “clinically rel-
evant improvement in pain” at the end of the ive-day study pe-
riod. A “clinically relevant improvement in pain” was defined as a
reduction in BPI average pain score by ≥ 2 points from baseline
in the absence of more than four breakthrough doses of analgesia
over the previous 24 hours. Secondary outcomes included pain
assessments at days two to five and adverse events.
See Characteristics of included studies tables.
Excluded studies
For this update we identified one eligible study (Hardy 2012),
which was included. Overall, we excluded five studies. (For studies
previously excluded see Characteristics of excluded studies).
Risk of bias in included studies
See Figure 2; Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The studies by Yang 1996 and Mercadante 2000 stated that pa-
tients were randomised to treatment and control groups, but in
neither trial was the process of randomisation described (unclear
risk of bias). In the trial by Hardy 2012 each site pharmacy used
randomisation tables from an independent central registry. Strat-
ification was by pain type (neuropathic or nociceptive) and ran-
domisation was double-blinded, allocated by blocks of four in a
1:1 ratio for each strata by site. We judged this study to be at low
risk of bias.
Blinding
Performance bias
Participants, investigators and nurses were blinded using a double-
dummy technique in Yang 1996 and the drugs were prepared
in identical syringes by a person not involved in the study and
administered in the same volume inMercadante 2000. TheHardy
2012 trial is described as double-blinded. The blinding procedure
was not described in the final paper, but was described in the study
protocol (“All syringes will look identical in volume and colour”).
There were no specific procedures to check for performance bias
in any of the three included trials. In Yang 1996, one partici-
pant in the morphine phase and no participants in the combined
morphine and ketamine phase reported psychotoxicity (hallucina-
tions), whereas in Mercadante 2000 ketamine caused hallucina-
tions in four of 10 participants, so the participants may have been
able to tell which drug they had received. The study by Hardy
2012 involved rapid dose escalation of ketamine to high doses
and blinding could have been compromised due to adverse effects
from ketamine. We judged the study by Yang 1996 at low risk of
performance bias and the studies by Mercadante 2000 and Hardy
2012 at unclear risk of performance bias.
Detection bias
We judged the study by Yang 1996 at low risk of detection bias
and the studies by Mercadante 2000 and Hardy 2012 at unclear
risk of detection bias.
Incomplete outcome data
All participants were accounted for in the trials by Yang 1996
and Mercadante 2000. Hardy 2012 reported an ITT analysis,
but imputed missing data using last observation carried forward
(LOCF). We judged this study at unclear risk of bias.
Selective reporting
There were no problems of selective reporting detected in the
trials by Mercadante 2000 and Yang 1996. In the trial by Hardy
2012, assessing “the effect of ketamine on total opioid dose” was
mentioned in the protocol as a “secondary objective”, but was not
reported. We judged this study at unclear risk of bias.
Other potential sources of bias
Size
The cross-over studies by Yang 1996 and Mercadante 2000 had
respectively 20 and 10 participants (fewer than 50 participants per
treatment arm). We judged these trials at high risk of bias. The
parallel group trial by Hardy 2012 had 185 participants (between
50 and 199 participants per treatment arm) and we judged it at
unclear risk of bias.
Oxford quality assessment
Quality scores derived using theOxford quality scale (Jadad 1996)
were three for both Mercadante 2000 and Yang 1996, and four
for Hardy 2012 out of a possible maximum of five points.
Using the method derived by Smith 2000, the three included
studies (Yang 1996; Mercadante 2000; Hardy 2012) scored 13,
12 and 12, respectively on the Oxford Pain Validity Scale, a zero
to 16-point validity scale.
Effects of interventions
It was not possible to perform a quantitative meta-analysis because
of the small number of participants in two of the trials, lack of
extractable data and general heterogeneity of the data. A descrip-
tion of the results from the three included trials is given below.
None of the trials provided data on pain relief, patient satisfaction/
preference, function or distress. For all outcomes we judged the
quality of the evidence to be very low. We downgraded one level
for serious risk of bias and two levels for very serious imprecision
due to very small number of participants in two of the compar-
isons and small number of participants in the third comparison.
Patient-reported pain intensity
Ketamine 1.0 mg twice daily (intrathecal)
One study (Yang 1996) assessed adjuvant ketamine 1.0 mg ad-
ministered intrathecally. The trial duration is not specified, but
it was conducted over several days. Pain intensity on a numerical
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rating scale zero to 10 was reduced from 7.95 ± 0.25 to 2.45 ±
0.17 after adjuvant treatment with ketamine.
Ketamine 0.25 mg/kg (intravenous)
One trial (Mercadante 2000) assessed pain intensity over three
hours. Mean pain intensity scores showed a reduction in pain
intensity after 30 minutes compared with saline solution; after 60
minutes the analgesic effect of ketamine began to diminish but
continued to have an effect for a period of three hours.
Ketamine 0.5 mg/kg (intravenous)
One trial (Mercadante 2000) assessed pain intensity over three
hours. Mean pain intensity scores showed a significant reduction
after 30 minutes compared with saline solution. The analgesic
effect of ketamine continued throughout the three-hour period.
Ketamine dose escalation 100 mg, 300 mg, 500 mg
(subcutaneous)
One study (Hardy2012) assessed averageBPI pain score onday six,
following dose escalation of ketamine subcutaneous infusion in a
five-day schedule, starting at the first dose level (100mg/24 hours).
If 80% of the study drug had been delivered, and average pain
improved by≥ 2 BPI units, with no more than four breakthrough
doses, the dose remained the same. If not, the dose was increased
to the next level. There was no significant difference in patient-
reported pain intensity between the placebo and ketamine arms.
Total opioid consumption
Ketamine 1.0 mg twice daily (intrathecal)
Yang 1996 reported that on the last day of the morphine phase,
participants required intrathecal morphine 0.38 mg/day ± 0.04
mg/day. On the last day of the combined ketamine and morphine
(K+M)phase, intrathecalmorphine requirements haddecreased to
0.17 mg/day ± 0.02 mg/day. The total titrated dose of intrathecal
morphine, total dose of intramuscular rescuemorphine during the
K+M phase was less than in the morphine phase.
Ketamine 0.25 mg/kg and 0.5 mg/ kg (intravenous)
Mercadante 2000 did not provide information on this outcome.
Ketamine dose escalation 100 mg, 300 mg, 500 mg
(subcutaneous)
Hardy 2012 did not provide information on this outcome.
Rescue medication
Ketamine 1.0 mg twice daily (intrathecal)
Yang 1996 reported that the total dose of rescue morphine during
the K+M phase was less than the morphine phase.
Ketamine 0.25 mg/kg and 0.5 mg/kg (intravenous)
Mercadante 2000 did not report the use of rescue medication, but
stated in the text that the administration of ketamine allowed for
“a reduction of opioid doses”.
Ketamine dose escalation 100 mg, 300 mg, 500 mg
(subcutaneous)
Hardy 2012 reported that there was no significant group differ-
ence in the median number of breakthrough analgesic doses given
during the study.
Adverse events
Psychomimetic adverse events
Ketamine 1.0 mg twice daily (intrathecal)
One participant in themorphine only arm of the Yang 1996 study
reported hallucinations. There were none reported in the ketamine
arm.
Ketamine 0.25 mg/kg and 0.5 mg/kg (intravenous)
In the study by Mercadante 2000, ketamine injection produced
hallucinations in four participants: three experienced hallucina-
tions whilst receiving 0.25 mg/kg and 0.5 mg/kg ketamine, and
one further participant experienced hallucinations when receiv-
ing ketamine 0.5 mg/kg. All were treated with diazepam 1 mg.
In addition, two participants experienced light flashes, a ’buzzing’
feeling in the head, and sensation of insobriety. Diazepam resolved
these symptoms. No significant changes in the Mini-Mental State
Examination (MMSE) were observed.
Ketamine dose escalation 100 mg, 300 mg, 500 mg
(subcutaneous)
In the study by Hardy 2012, there was almost twice the incidence
of adverse events in the ketamine arm compared with the placebo
arm on day one and throughout the study. Psychomimetic adverse
events were assessed daily using the Clinician-Administered Dis-
sociative States Scale (CADSS). CADSS scores were not reported
but 17 cognitive disturbance events with grading worse than at
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baseline were recorded in the ketamine group and eight such events
were recorded in the placebo group. Thirteen confusion events
with grading worse than baseline were recorded in the ketamine
group and nine such events were recorded in the placebo group.
Psychomimetic toxicity was treated with haloperidol or midazo-
lam at specified doses.
Other adverse events
Ketamine 1.0 mg twice daily (intrathecal)
On direct questioning, participants reported a number of adverse
effects during the trial conducted by Yang 1996:
• pruritis;
• constipation;
• urinary retention;
• difficulty in urinating;
• nausea and vomiting;
• hallucinations;
• respiratory depression.
However, these adverse events could not be attributed specifically
to the study treatments as some were present prior to the com-
mencement of the study.
Ketamine 0.25 mg/kg and 0.5 mg/kg (intravenous)
Information on the following adverse events were sought in the
trial conducted by Mercadante 2000:
• drowsiness;
• nausea and vomiting;
• dry mouth.
These adverse events were assessed on a scale from zero to three,
where zero was ’not at all’, and three was ’awful’. Participants
treated with 0.25 mg/kg and 0.5 mg/kg ketamine reported in-
creased drowsiness.
Ketamine dose escalation 100 mg, 300 mg, 500 mg
(subcutaneous)
In the trial by Hardy 2012, adverse events were graded according
to the National Institutes of Health Common Terminology Cri-
teria for Adverse Events, version 3.0 (Cancer Therapy Evaluation
Program Version 3). There was almost twice the incidence of ad-
verse events in the ketamine arm compared with the placebo arm
at the end of day one and throughout the study. The authors re-
ported 31 episodes of injection site reactions, which were reported
as nearly three times more likely than the placebo group. There
were relatively few adverse events higher than grade three in sever-
ity (14 for ketamine; 16 for placebo). Seven serious adverse events
were reported, two of which (bradyarrhythmia and cardiac arrest,
both in participants receiving ketamine) were thought to be pos-
sibly related to the study drug.
Both the trial by Yang 1996 and the trial by Mercadante 2000
reported that the adverse events of ketamine were not serious.
Study withdrawals and dropouts
No study withdrawals or dropouts were reported in either trial
by Yang 1996 or Mercadante 2000. In the study by Hardy 2012,
39 participants in the ketamine group and 55 participants in the
placebo group withdrew from the trial. Sixteen participants in
each group discontinued the study due to clinical deterioration,
patient/ clinical request or change in therapy. Nineteen partici-
pants in the ketamine group and 37 participants in the placebo
group discontinued due to treatment failure. Of these, 17 in the
ketamine group and two in the placebo group discontinued due
to toxicity.
D I S C U S S I O N
Summary of main results
There are three included studies in the current version of the re-
view. Two small early studies Yang 1996 and Mercadante 2000
report reduction in pain intensity and reduction in morphine re-
quirements. These two studies are of high risk of bias due to small
sample size, and incomplete reporting. The new study fromHardy
2012 has unclear risk of bias due to size and incomplete report-
ing. Hardy 2012 reports no difference in their primary outcomes
between groups. Overall, we cannot provide a reliable indication
of the likely effect of ketamine, at any dose, as an adjuvant to
opioids in cancer pain. Adverse events such as hallucinations and
cognitive disturbance were reported for higher doses of ketamine.
Two serious adverse events (bradyarrhythmia and cardiac arrest)
reported in the trial examining rapid titration of ketamine to high
dose were thought to be possibly related to the study drug.
There is large body of evidence demonstrating the efficacy of ke-
tamine in acute postoperative pain. While this evidence cannot
be directly extrapolated to other patient groups, it is important to
note the complex pathophysiology of cancer pain and the difficul-
ties of conducting clinical trials in palliative care. The authors of
the study by Hardy 2012 should be commended for recruiting an
impressive number of participants. The data from this trial could
potentially provide further information on clinical questions such
as whether ketamine has beneficial interactions with specific opi-
oids, since both preclinical and clinical research have suggested
that this is the case when ketamine is used as an adjuvant to mor-
phine (Lilius 2015). To date, the fact that the participants in the
Hardy 2012 trial used different opioids has not been addressed
and the subgroup analyses based on type and dose of opioid have
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not been reported. We contacted the authors with a request for
access to individual patient data, however the request was declined
because such analyses were not stated in our original protocol for
this review.
It is worth noting, also, that the dose escalation in theHardy 2012
trial was very rapid, considering the pharmacokinetics of ketamine
which has a short α half-life (two to four minutes) and longer β
half-life (two to four hours) in humans (Peltoniemi 2016), and
where steady state is achieved after five elimination half-lives. The
metabolite norketamine, which is also active has a much longer
half-life than ketamine, and very ill cancer patients would be likely
to have a much poorer elimination than young healthy volunteers.
Ketamine doses in the Hardy 2012 trial were higher than those
used in the majority of ketamine regimens described in the litera-
ture. It is interesting that ketamine was found to have better effect
in patients with high pain scores, however this was not mentioned
in the abstract. The same finding is reported in a systematic re-
view of 70 randomised controlled trials of intravenous ketamine
for postoperative analgesia (Laskowski 2011). In clinical practice,
ketamine is usually considered to be a third-line drug which is
reserved for patients with high pain intensity scores, despite ade-
quate ongoing opioid therapy and co-analgesics. Hardy 2012 in-
cluded patients with a BPI pain intensity score of three at baseline
and also patients being treated with comparatively low doses of
opioid.
All three trials used pain intensity scores as the primary outcome.
Percentage pain relief may be a more useful and reliable outcome
measure (Dworkin 2008).
Other reports considered in the original review (2003)
Because of the paucity of data available from RCTs in the original
review, we considered information presented in case studies and
case series reports of ketamine for chronic cancer pain. In addition
to the two RCTs included, the original review (2003) identified 32
case reports or open-label, uncontrolled trials describing improve-
ment of opioid analgesia with ketamine. We did not consider case
studies and reports in the updated review.
Whilst the design of these studies and the issue of publication of
positive outcomes preclude the inclusion of any data from these
reports in this systematic review, the studies were discussed in
the original review and are reported in this update in order to
provide amore comprehensive reviewof the literature on this topic.
Case reports cannot provide evidence for efficacy but may provide
valuable information on adverse effects. They are, by definition,
all of low quality.
The 32 reports described the use of ketamine to treat refractory
cancer pain, frequently described as neuropathic pain. The to-
tal number of participants treated with ketamine in these reports
was 246. The route of ketamine administration included oral, in-
tramuscular bolus, subcutaneous bolus and infusion, intravenous
bolus and infusion, epidural bolus, and intrathecal infusion. Ke-
tamine doses ranged from 1 mg/kg/day subcutaneous infusion to
600 mg/day intravenously and 67.2 mg/day intrathecally. Treat-
ment duration ranged from four hours to one year. Treatment was
in most cases adjuvant to opioid and other drugs. Twenty-eight
reports described improved analgesia with ketamine. Where ke-
tamine was administered as an adjuvant to opioids, the most com-
monly used opioid was morphine, but in some cases ketamine was
given as an adjuvant to fentanyl (Ventura 1993; Bell 1999), hydro-
morphone (Fine 1999) or diamorphine (Garry 1996), or combi-
nations of these. Ketamine was also used as sole analgesic in three
reports (Parada 1971;Whizar-Lugo 1987; Oshima 1990). Sixteen
reports described dramatic relief of refractory cancer pain with ke-
tamine: “complete cessation of pain” (Ventura 1993); “complete
relief of pain” (Tarumi 2000); “disappearance of pain” (Parada
1971; Garry 1996); “no pain” (Fine 1999); “pain free” (Mitchell
1999),; “mostly pain free” (Lloyd-Williams 2000); dramatic re-
duction in visual analogue scales (VAS) scores including VAS 100
reduced to zero (Bell 1999); average VAS score 8.3 reduced to
one (Kanamaru 1990); average VAS score reduced from 5.9 +/
- 2.0 to 0.3 +/- 0.8 (Ogawa 1994); VAS 7/10 reduced to 1/10
(Wood 1997); reduction of VAS 7/10 to below 2/10 (Lossignol
1999); “dramatic drop in VAS” (Lossignol 1992); “remarkable
analgesia” (Fukuida 1981); “excellent analgesia” (Sosnowski 1993;
Mercadante 1995).
Themost commonly reported adverse events in this literature were
sedation and hallucination. In general, adverse events were not
reported as severe and only two studies reported patient with-
drawal from treatment because of unacceptable “adverse cognitive
effects” (Garry 1996), and pronounced sedation (Klahr 1997).
One report described sedation which improved on tapering the
opioid dose (Bell 1999). Other side effects described included
evoked nystagmus (jerky eye movements) during treatment with
intravenous ketamine (Lossignol 1999), and inflammation of sy-
ringe driver sites during subcutaneous treatment (Oshima 1990;
Mitchell 1999).One report described generalised hyperalgesia and
allodynia after abrupt termination of subcutaneous ketamine in-
fusion (Mitchell 1999). One postmortem report described subpial
vacuolar myelopathy in a participant who had received contin-
uous intrathecal ketamine infusion (Karpinski 1997), while an-
other described focal lymphocytic vasculitis close to the intrathe-
cal catheter site (Stotz 1999). One report described maintenance
of syringe driver sites with topical 0.1% hydrocortisone cream
(Lloyd-Williams 2000).
Overall completeness and applicability of
evidence
The two small studies (30 participants) included in the original
review provided insufficient data to enable any evidence-based
conclusions about the benefits and harms of adjuvant ketamine
to be drawn. The larger trial by Hardy 2012 reported negative
outcomes for a rapid titration, high-dose ketamine regimen.
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Quality of the evidence
The evidence from this review is limited to three very different
studies which could not be combined. There are two very small
studies undertaken in the 1990s of low-dose ketamine, and one
larger multi-centre modern trial reported in 2012 on rapid titra-
tion of ketamine to high dose. Overall, the quality of the evidence
base is very low and cannot provide a reliable indication of any
likely effect across outcomes.
Potential biases in the review process
We are unaware of any potential biases in the review process.
Agreements and disagreements with other
studies or reviews
A qualitative systematic review of ketamine for cancer pain in
adults and children concluded that despite limited available data,
there is evidence that ketamine may be a “viable option” for cancer
pain that is poorly responsive to opioid therapy, that it appears
to contribute to decreased opioid use and improved pain control
(Bredlau 2013). The authors of this review specifically wanted to
perform a comprehensive review of all available data. They in-
cluded the same three RCTs included in our review and in addi-
tion, two trials whichwere excluded by our review (Lauretti 1999a;
Lauretti 1999b) (see Characteristics of excluded studies). They
also included six prospective, non-randomised, uncontrolled trials
and one retrospective case series of more than 10 participants.
A recent systematic review on adjuvant analgesics for cancer pain
found that there is low-grade evidence suggesting that ketamine
as an adjuvant to opioid in cancer pain leads to pain reduction,
but conclude that there is generally insufficient evidence on the
effectiveness of NMDA receptor antagonists in cancer pain (van
den Beuken-van Everdingen 2017). This review considered our
Cochrane update from 2012, the review by Bredlau 2013, and a
RCT excluded from our last update (Salas 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with refractory cancer pain treated with
opioid
The evidence base for ketamine as an adjuvant to opioids for the
treatment of cancer pain is insufficient to enable us to draw any
conclusions. Rapid dose escalation of ketamine to high dose (500
mg) does not appear to have clinical benefit and may be associated
with serious adverse events.
For clinicians
The evidence base for ketamine as an adjuvant to opioids for the
treatment of cancer pain is insufficient to enable us to draw any
conclusions. Rapid dose escalation of ketamine to high dose (500
mg) does not appear to have clinical benefit and may be associated
with serious adverse events.
For policy makers
The evidence base for ketamine as an adjuvant to opioids for the
treatment of cancer pain is insufficient to enable us to draw any
conclusions. Rapid dose escalation of ketamine to high dose (500
mg) does not appear to have clinical benefit and may be associated
with serious adverse events.
For funders of the intervention
The majority of this patient group are commonly in-patients, due
to refractory symptoms. Ketamine administered to hospitalised
patients is an inexpensive treatment. However, the evidence base
for ketamine as an adjuvant to opioids for the treatment of cancer
pain is insufficient to enable us to draw any conclusions.
Implications for research
General implications
The amount of clinical trial evidence in this review is limited.
Studies investigating specific low-dose ketamine treatment regi-
mens commonly used for refractory cancer pain are needed.
Design
Conducting scientifically sound trials in a population of terminally
ill cancer patients is a considerable challenge, and this is perhaps
reflected in the small number of published trials available for this
review. It is difficult to recruit large numbers of patients from this
population. Cross-over designs, as used in the two of the three in-
cluded studies, may be more appropriate than placebo-controlled
parallel group studies. Where there are large trials, planned sub-
group analyses should be considered.
Measurement (endpoints)
Outcomes should be clearly defined, and trial managers should
also restrict study outcomes to those that are the most clinically
useful, such as which route of administration, relevant dose, co-
analgesic effects with specific opioids, and the cost to the patient
in terms of adverse events.
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Whether ketamine is more effective in combination with specific
opioids is not known, and this is an area for further research. Rapid
titration of ketamine to high dose (Hardy 2012) had no clinical
benefit and was associated with adverse events. Further studies
examining this specific treatment regimen are not warranted. Trials
with S-ketamine as an adjuvant to opioids might be appropriate.
Other
Opioid tolerance may also be an issue. It has been suggested that
pharmacological tolerance to opioid can develop early (Laulin
2002), but it is not clear how often it is a clinical problem in
cancer patients. It may be difficult in this patient population to
distinguish between tolerance and disease progression, both of
which require an increase in opioid dose. In patients who appear
to have a problem tolerating opioids, ketamine in low dose may
be a treatment option. This is a topic for future research.
More information is needed on whether the route of administra-
tion of ketamine has an impact on its effectiveness as an analgesic.
If ketamine is used spinally, issues of neurotoxicity should be con-
sidered (Karpinski 1997).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hardy 2012
Methods Randomised.
Double-blind, but blinding procedure not described.
Placebo control.
Parallel group
Study duration 5 days
Participants Inpatients aged 18 or older, palliative care patients with refractory chronic pain (BPI
average pain score ≥3 despite ongoing treatment with opioids and co-analgesics at pre-
defined dose levels) secondary to cancer or its treatment
N= 185, 93 randomised to ketamine group, 92 randomised to placebo
Mean age in ketamine arm: 63 years. Mean age in placebo group: 64.3
Interventions Participants received either ketamine or placebo (normal saline) as a subcutaneous infu-
sion in a 5-day schedule, starting at the first dose level (100 mg/24 hrs. If 80% of the
study drug had been delivered, and average pain improved by ≥ 2 BPI units, with no
more than four breakthrough doses, the dose remained the same. If not, the dose was
increased to the next level
Outcomes The primary outcome was a positive response, defined as a clinically relevant improve-
ment in pain at the end of the 5-day study period. A clinically relevant improvement in
pain was defined as a reduction in BPI average pain score by ≥ 2 points from baseline
in the absence of more than four breakthrough doses of analgesia over the previous 24
hours. Secondary outcomes: pain assessments at days 2-5. Adverse events
Notes Data for patients who discontinued due to reasons unrelated to the intervention were
imputed using LOCF. Unclear how data for those who discontinued due to adverse
effects or lack of effect were handled
Quality/validity:
OPVS: 12
Oxford: 4
Supported by a grant from the Palliative Care Branch, Australian Government Depart-
ment of Health and Ageing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, process of randomisation is
described and adequate. “Each site phar-
macy used randomization tables from an
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Hardy 2012 (Continued)
independent central registry”
Allocation concealment (selection bias) Low risk “All non pharmacy study staff, treat-
ing clinicians,investigators and participants
were unaware of treatment allocation until
completion”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as blinded. Blinding procedure
not described in final paper but was de-
scribed in protocol “All syringes will look
identical in volume and colour”. The au-
thors of this review update felt that blind-
ing could have been compromised due to
adverse effects from ketamine
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific procedure to check for detec-
tion bias. The authors of this review update
felt that blinding could have been compro-
mised due to adverse effects from ketamine
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how missing data were imputed
Selective reporting (reporting bias) Unclear risk Total opioid dose was not reported but was
mentioned in the protocol
Size Unclear risk 50 - 199 participants per treatment arm
Mercadante 2000
Methods Stated to be randomised but procedure not described.
Blinded study: Drugs prepared in identical syringes by a person not involved in the test
sessions
Placebo control
Cross-over
Study duration:
30 to 180 minutes
Participants Cancer patients with neuropathic pain unrelieved by morphine
N = 10 per group (cross-over)
Mean age of patients: 57 years
Interventions Treatment 1:
Saline (IV)
Treatment 2:
KET bolus 0.25 mg/kg (IV)
Treatment 3: KET bolus 0.5 mg/kg (IV)
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Mercadante 2000 (Continued)
Outcomes Pain intensity
Adverse effects
Results:
Low-dose KET IV + Mo (PO, SC, IV) significantly reduced pain intensity
Notes Washout period ( “at least two days”)
Quality/ validity:
OPVS score: 12
Oxford score: 3
Information on funding not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised but procedure not
described.
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The drugs were prepared in identical sy-
ringes by a person not involved in the test
sessions”. Blinding possibly compromised
due to adverse effects from ketamine
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific procedure to check for detec-
tion bias. Possible bias due to adverse ef-
fects from ketamine
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk No problems detected
Size High risk Fewer than 50 participants in total (cross-
over)
Yang 1996
Methods Stated to be randomised but procedure not described.
Blinded study: double dummy
Cross-over, no washout
Active control (morphine)
Study duration: not defined
Participants Hospitalised patients with terminal cancer pain, treated with opioids
N = 20 per group (cross-over)
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Yang 1996 (Continued)
Interventions Treatment 1:
Mo (IT)
Treatment 2:
KET 1.0 mg (IT) twice daily + Mo (IT)
Outcomes Pain intensity
Pain frequency
Total titrated Mo dose (IT).
Total rescue medication.
Frequency of IT titration.
Results:
Co-administration of low-dose KET reduces the amount of IT Mo required to control
cancer pain
Notes No washout period
Quality/ validity:
OPVS score: 13
Oxford score: 3
Supported by a grant from the National Science Council (NSC), Taipei, Taiwan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised but procedure not
described
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A doubled dummy technique was used,
so that the patient, investigator and nurse
were unaware of the dose of morphine and
ketamine”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A doubled dummy technique was used,
so that the patient, investigator and nurse
were unaware of the dose of morphine and
ketamine”. Blinding not compromised by
adverse effects from ketamine
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk No problems detected
Size High risk Fewer than 50 participants in total (cross-
over)
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BPI: Brief Pain Inventory
IT: Intrathecal
IV: Intravenous
KET: Ketamine
kg: Kilo
LOCF:Last observation carried forward
mg: Milligram
Mo: Morphine
N: Number of patients
OPVS: Oxford Pain Validity Scale
PO: Oral
SC: Subcutaneous
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Currow 2011 Poster abstract
Ishizuka 2007 Dropouts leaving one group with fewer than 10 participants
Lauretti 1999a Open-label study (“pilot work”). Described as placebo-controlled, but in fact used active control (morphine).
Design flaw with fixed maximum baseline morphine dose PO and primary outcome measure: daily consumption
of morphine. OPVS score: 1 Oxford Quality Scale score: 2
Lauretti 1999b Described as placebo-controlled, but in fact used active control (morphine). Design flaw with fixed baseline dose
of morphine ED, fixed maximum daily dose of morphine ED and primary outcome measure: daily consumption
of morphine ED. OPVS score: 7 Oxford Quality Scale score: 3
Salas 2012 Dropouts leaving one group with fewer than 10 participants
ED: epidural
OPVS: Oxford Pain Validity Scale
PO: oral
Characteristics of ongoing studies [ordered by study ID]
NCT00484484
Trial name or title Ketamine associated with opioids in refractory cancer pain treatment
Methods Randomised, placebo-controlled, double-blind parallel group study
Participants 100 hospitalised adult cancer patients undergoing opioid treatment for refractory pain
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NCT00484484 (Continued)
Interventions Ketamine versus placebo
Outcomes Daily pain score on 11-point numerical pain rating scale; patient global impression of change; daily sleep
interference score;patient satisfaction; opioid consumption; adverse effects
Starting date May 2007. Completed September 2009
Contact information Sylvie Rostaing-Rigattieri, Assistance Publique- Hopitaux de Paris, Paris, France
Notes Status ’completed’. Not published. Possibly same study as NCT01326325?
NCT01207206
Trial name or title Oral ketamine as an adjuvant to opioids for pain treatment in cancer patients
Methods Randomised, placebo-controlled, double-blind study
Participants 50 patients with unbalanced (VAS > 6) chronic cancer-related pain despite opioid treatment
Interventions Oral ketamine versus placebo
Outcomes Pain reduction (VAS scores), adverse effects
Starting date October 2010
Contact information Silviu Brill, Tel Aviv Sourasky Medical Center
Notes
NCT01316744
Trial name or title Ketamine hydrochloride and best pain management in treating cancer patients with neuropathic pain
Methods Randomised, placebo-controlled, double-blinded, parallel group study
Participants Adult cancer patients with malignant neuropathic pain
Interventions Addition of ketamine hydrochloride or placebo to “best pain management”
Outcomes Time to treatment failure; difference in pain scores; patient distress; adverse effects
Starting date April 2009
Contact information Marie T. Fallon, Edinburgh Cancer Centre at Western General Hospital, Edinburgh, UK
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NCT01316744 (Continued)
Notes Unknown status
NCT01326325
Trial name or title Efficacy of low analgesic doses of ketamine associated with opioids in refractory cancer pain treatment
Methods Randomised, placebo-controlled, double-blind parallel group study
Participants Adult hospitalised cancer patients with refractory pain undergoing opioid treatment
Interventions IV ketamine versus placebo
Outcomes Per cent reduction average daily pain intensity score; daily average pain intensity score; patient global impres-
sion of change; daily sleep interference; opioid consumption; patient satisfaction; adverse effects
Starting date July 2011. Completed February 2013
Contact information Sylvie Rostaing-Rigattieri, Center of Evaluation and Treatment of Pain, Saint-Antoine Hospital, Paris, France
Notes “Completed” study, unpublished. Possibly the same study registered as NCT00484484?
NCT02591017
Trial name or title Comparison of oral morphine versus nasal ketamine spray with chitosan in cancer pain outpatients
Methods Randomised, placebo-control double blind cross-over study
Participants 34 adult cancer outpatients with opioid base therapy because of pain, or pain breakthrough pain or extreme
pain on movement
Interventions 3 treatment arms investigating morphine drops, ketamine nasal spray with chitosan or morphine drops +
ketamine nasal spray with chitosan
Outcomes Time to onset of action; median numeric rating scale (NRS) improvement; total dose ketamine or morphine;
total opioid dose increase; adverse effects
Starting date February 2015
Contact information Wilhelm Ruppen, Pain Relief Unit and Anesthesiology, University Hospital Basel, Switzerland
Notes
IV: intravenous
VAS: visual analogue scale
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy - 2002
via OVID
1. KETAMINE (single term MeSH)
2. ketamine or inducmina or ketalar or ketanest or calypso or narkamon or keta or velonarcon or ketmin or ketava or ketalin or
ketina or brevinaze or keta-hameln
3. OR/1-2
4. Explode NEOPLASMS
5. BONE MARROW TRANSPLANTATION (single term MeSH)
6. neoplas* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or
malignan* or bone-marrow-transplant* or “bone marrow transplant*”
7. Explode RADIOTHERAPY
8. radiotherap* or radiation or irradiat* or radiochemo* or chemotherapy*
9. OR/4-8
10. 3 AND 9
The above subject search was linked to the Cochrane Sensitive Search strategy filter for RCTs:
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trials.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single blind method.sh.
7. or/1-6
8. (ANIMALS not HUMAN).sh.
9. 7 not 8
10. clinical trial.pt.
11. exp clinical trials/
12. (clin* adj25 trial*).ti,ab.
13. ((singl* or doubl* or trebl* or tripl*) adj25 (blind* or mask*)).ti,ab.
14. placebos.sh.
15. placebo*.ti,ab.
16. random*.ti,ab.
17. research design.sh.
18. or/10-17
19. 18 not 8
20. 19 not 9
21. 9 or 19
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Appendix 2. Other search strategies - 2002
Database search strategy
PaPaS Trials register ((ketamine or inducmina or ketalar or ketanest or calypso or narka-
mon or keta or velonarcon or ketmin or ketava or ketalin or ketine
or brevinaze or keta-hameln) AND (neoplas* or cancer* or car-
cinoma* or tumour* or tumor* or adenocarcinoma* or leukemi*
or leukaemi* or lymphoma* or malignan* or bone-marrow-trans-
plant* or “bone marrow transplant*” or radiotherap* or radiation
or irradiat* or radiochemo* or chemotherap*))
CENTRAL #1 KETAMINE (single term MeSH)
#2 ketamine or inducmina or ketalar or ketanest or calypso or
narkamon or keta or velonarcon or ketmin ketava or ketalin or
ketina or brevinaze or keta-hameln
#3 #1 or #2
#4 Explode NEOPLASMS
#5 BONE MARROW TRANSPLANT (single term MeSH)
#6 neoplas* or cancer* or carcinoma* or tumour* or tumor* or
adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or
malignan* or bone-marrow-transplant* or “bone marrow trans-
plant*”
#7 Explode RADIOTHERAPY
#8 radiotherap* or radiation or irradiat* or radiochemo* or
chemotherap*
#9 #4 or #5 or #6 or #7 or #8
#10 #3 AND #9
PubMed (for limit to Cancer subset) #1 Search KETAMINE Field: MeSH Terms
#2 Search ketamine or inducmina or ketalar or ketanest or calypso
or narkamon or keta or velonarcon or ketmin ketava or ketalin or
ketina or brevinaze or keta-hameln
#3 Search #1 or #2
#4 Search NEOPLASMS Field: MeSH Terms
#5 Search BONE MARROW TRANSPLANTATION Field:
MeSH Terms
#6Search neoplas* or cancer* or carcinoma* or tumour* or tumor*
or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or
malignan* or bone-marrow-transplant* or “bone marrow trans-
plant*”
#7 Search RADIOTHERAPY Field: MeSH Terms
#8 Search radiotherap* or radiation or irradiat* or radiochemo*
or chemotherap*
#9 Search #4 or #5 or #6 or #7 or #8
#10 Search #3 AND #9
#11 Search (randomized controlled trial [pt] OR controlled clin-
ical trial [pt] OR randomized controlled trials [mh] OR random
allocation [mh] OR double-blind method [mh] OR single-blind
method [mh] OR clinical trial [pt] OR clinical trials [mh] OR
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(Continued)
(“clinical trial” [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl*
[tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR
(placebos [mh] OR placebo* [tw] OR random* [tw] OR research
design [mh:noexp]) NOT (animals [mh] NOT humans [mh])
#12 #10 AND #11 Limit CANCER subset
Embase via OVID 1 KETAMINE (single term MeSH)
2 ketamine or inducmina or ketalar or ketanest or calypso or
narkamon or keta or velonarcon or ketmin or ketava or ketalin or
ketina or brevinaze or keta-hameln
3 OR/1-2
4 Explode NEOPLASM
5 BONE MARROW TRANSPLANTATION (single term
MeSH)
6 neoplas* or cancer* or carcinoma* or tumour* or tumor* or ade-
nocarcinoma* or leukemi* or leukaemi* or lymphoma* or malig-
nan* or bone-marrow-transplant* or “bone marrow transplant*”
7 Explode RADIOTHERAPY
8 radiotherap* or radiation or irradiat* or radiochemo* or che-
motherapy*
9 OR/4-8
10 3 AND 9
The above subject search was linked to the following
Filter for EMBASE via OVID
1. random*.ti,ab.
2. factorial*.ti,ab.
3. (crossover* or cross over* or cross-over*).ti,ab.
4. placebo*.ti,ab.
5. (doubl* adj blind*).ti,ab.
6. (singl* adj blind*).ti,ab.
7. assign*.ti,ab.
8. allocat*.ti,ab.
9. volunteer*.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERI-
MENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18
THE PFIZER PRODUCT INFORMATION DATABASE
(PPI) (2002-2007)
1 ((KETAMINE OR KETALAR) AND (CANCER* OR NEO-
PLASM* OR TUMOR* OR TUMOUR* OR CARCINOMA*
OR MALIGNAN*)).AF 415
2 LIMIT ((KETAMINEORKETALAR) AND (CANCER*OR
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(Continued)
NEOPLASM* OR TUMOR* OR TUMOUR* OR CARCI-
NOMA* OR MALIGNAN*)). AF TO YR=2002-2007 62
Appendix 3. CENTRAL search strategy - 2012
#1 MeSH descriptor Ketamine explode all trees
#2 (ketamine or inducmina or ketalar or ketanest or calypso or narkamon or keta or velonarcon or ketmin or ketava or ketalin or ketina
or brevinaze or keta-hameln):ti,ab,kw
#3 (#1 OR #2)
#4 MeSH descriptor Neoplasms explode all trees
#5 (neoplas* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* ormalignan*):
ti,ab,kw
#6 (#4 OR #5)
#7 (#3 AND #6)
Appendix 4. Embase search strategy - 2012
Embase <1996 to May 2012
1 exp KETAMINE/
2 (ketamine or inducmina or ketalar or ketanest or calypso or narkamon or keta or velonarcon or ketmin or ketava or ketalin or ketina
or brevinaze or keta-hameln).tw.
3 or/1-2
4 exp neoplasm/
5 (neoplas* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or malig-
nan*).tw.
6 or/4-5
7 3 and 6
8 Clinical trial/
9 Randomized controlled trial/
10 Randomization/
11 Single blind procedure/
12 Double blind procedure/
13 Crossover procedure/
14 Placebo/
15 randomi?ed controlled trial*.tw.
16 RCT.tw.
17 random allocation.tw.
18 randomly allocated.tw.
19 allocated randomly.tw.
20 (allocated adj2 random).tw.
21 single blind*.tw.
22 double blind*.tw.
23 ((treble or triple) adj blind*).tw.
24 placebo*.tw.
25 Prospective study/
26 or/8-25
27 Case study/
28 case report.tw.
29 abstract report/ or letter/
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30 or/27-29
31 26 not 30
32 7 and 31
33 (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011*).em.
34 32 and 33
Appendix 5. MEDLINE search strategy - 2012
Database: Ovid MEDLINE(R) without Revisions <1996 to May 2012
1 exp Ketamine/
2 (ketamine or inducmina or ketalar or ketanest or calypso or narkamon or keta or velonarcon or ketmin or ketava or ketalin or ketina
or brevinaze or keta-hameln).tw.
3 or/1-2
4 exp Neoplasms/
5 (neoplas* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or malig-
nan*).tw.
6 or/4-5
7 3 and 6
8 randomized controlled trial.pt.
9 controlled clinical trial.pt.
10 randomized.ab.
11 placebo.ab.
12 clinical trials as topic.sh.
13 randomly.ab.
14 trial.ti.
15 or/8-14
16 exp animals/ not humans.sh.
17 15 not 16
18 7 and 17
19 (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011*).ed.
20 18 and 19
Appendix 6. Searches 2017
CENTRAL (CRSO)
MESH DESCRIPTOR Ketamine
(ketamine or inducmina or ketalar or ketanest or calypso or narkamon or keta or velonarcon or ketmin ketava or ketalin or ketina or
brevinaze or keta-hameln):TI,AB,KY
#1 OR #2
MESH DESCRIPTOR NEOPLASMS EXPLODE ALL TREES
MESH DESCRIPTOR BONE MARROW
MESH DESCRIPTOR Bone Marrow Transplantation
(neoplas* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or malignan*
or bone-marrow-transplant* or “bone marrow transplant*”):TI,AB,KY
MESH DESCRIPTOR RADIOTHERAPY EXPLODE ALL TREES
( radiotherap* or radiation or irradiat* or radiochemo* or chemotherap*):TI,AB,KY
#4 OR #5 OR #6 OR #7 OR #8 OR #9
#3 AND #10
MEDLINE (OVID)
1. Ketamine/
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2. (ketamine or inducmina or ketalar or ketanest or calypso or narkamon or keta or velonarcon or ketmin or ketava or ketalin or ketina
or brevinaze or keta-hameln).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
3. 1 or 2
4. exp Neoplasms/
5. Bone Marrow Transplantation/
6. (neoplas* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or malignan*
or bone-marrow-transplant* or “bone marrow transplant*”).mp. [mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique
identifier]
7. exp Radiotherapy/
8. (radiotherap* or radiation or irradiat* or radiochemo* or chemotherapy*).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier]
9. or/4-8
10. 3 and 9
11. randomized controlled trial.pt.
12. controlled clinical trial.pt.
13. randomized.ab.
14. placebo.ab.
15. drug therapy.fs.
16. randomly.ab.
17. trial.ab.
18. groups.ab.
19. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. exp animals/ not humans.sh.
21. 19 not 20
22. 10 and 21
Embase (OVID)
1. ketamine/
2. (ketamine or inducmina or ketalar or ketanest or calypso or narkamon or keta or velonarcon or ketmin or ketava or ketalin or ketina
or brevinaze or keta-hameln).tw.
3. 1 or 2
4. exp neoplasm/
5. (neoplas* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or malig-
nan*).tw.
6. or/4-5
7. 5 or 6
8. 3 and 7
9. random$.tw.
10. factorial$.tw.
11. crossover$.tw.
12. cross over$.tw.
13. cross-over$.tw.
14. placebo$.tw.
15. (doubl$ adj blind$).tw.
16. (singl$ adj blind$).tw.
17. assign$.tw.
18. allocat$.tw.
19. volunteer$.tw.
20. Crossover Procedure/
21. double-blind procedure.tw.
22. Randomized Controlled Trial/
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23. Single Blind Procedure/
24. or/9-23
25. (animal/ or nonhuman/) not human/
26. 24 not 25
27. 8 and 26
F E E D B A C K
Feedback received, 20 July 2017
Summary
Name: David Currow
Email Address: david.currow@sa.gov.au
Affiliation: Flinders University
Role: Professor of Palliative & Supportive Services
Comment
The systematic review has suggested that ‘Hardy et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and
toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology 2012;30(29):3611-7’ is low level
evidence. Using the Cochrane Grade tool, it is not clear how this could be the conclusion given the parameters that are included in the
tool. The tool is copied below and the way the design and conduct of the study was undertaken is outlined in detail for each.
Methods of sequence generation
At each centre, patients were sequentially allocated a patient number on referral to the study. This number was kept within the Patient
Master Index, linking the patient name with the number allocated. Strata tables were developed for each site using random number
tables, generated at an independent centre (central registry). Treatment for each patient was allocated according to a block randomisation
(blocks of 4) schedule held by the central registry in a 1:1 ratio. Block randomisation ensured even allocation to each code. The central
registry supplied strata tables to each site pharmacy. Stratification was according to pain type: (neuropathic or nociceptive), according to
the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale. On notification of a participant, the pharmacist at each site
consulted the strata table according to the strata determined by the LANSS scale score, and allocated the next code available according
to the supplied strata table and prepared the active or inactive drug delivered in a labeled syringe. The participant ID, allocation code,
dates of request, preparation, and dispensing were recorded in a log maintained by the pharmacist.
Allocation concealment
At all times, from eligibility screening to completion of the study, all study staff are unaware of the treatment allocation. Allocation was
concealed from the investigator at the time of the participant inclusion in the trial.
Blinding - Participants
All syringes were prepared according to the randomisation schedule. Each syringe was numbered according to the pre-determined
randomisation code and labelled as ketamine/placebo 100mg, 300mg or 500mg in normal saline according to the prescription from
the investigator. All syringes looked identical in volume and colour to preserve the blinding irrespective of the contents. Study syringes
were supplied to the inpatient units and stored in a locked cupboard that met state regulations for this schedule of drug.
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Blinding - Providers
Treatment allocation was not disclosed to study staff, treating clinicians or investigators at any stage during the study.
Blinding - Outcome assessors
There were no cases of extreme emergency where knowledge of the code would have had significant consequences with respect to clinical
decision making. Therefore, no unblinding occurred during the study. Adverse events including skin toxicity and psychomimetic events
were documented in patients in both arms. Therefore it was not possible to differentiate clinically between arms.
Loss to follow up
No patient was lost to follow up. Those participants who had completed 24 hours at maximum dose (500 mg/24 hours) without a
response were deemed to have completed the study as continuation on ineffective treatment was considered unethical. Similarly, those
participants with unacceptable toxicity could complete prior to end day 5.
Failure to follow intention to treat principles in analyses. All eligible randomised participants were included in the primary ITT analysis.
Four patients who were randomised, but withdrew before the commencement of study drug were deemed to have had a negative
response.
Selective outcome reporting of outcomes and/or analyses
There was no difference in oral morphine equivalent doses between arms at baseline. Trial patients continued their current opioid
regimen throughout the study period with breakthrough/rescue doses as below. Patients continued all adjuvant analgesics at pre-study
dose throughout the duration of the study. Patients who required the addition of a new agent or in increase in co-analgesia during
the 5 day study period had the study treatment ceased. A reduction in co-analgesia because of toxicity was acceptable. Any changes in
concomitant medication was documented in the Rescue medications. Immediate release oral or subcutaneous opioid of up to 1/6th the
total daily dose ofmorphine or oxycodone were available q2hourly for all patients, preferably by the same route as the regular medication.
For patients on transdermal fentanyl, oral /subcutaneous oxycodone or morphine at doses as recommended by the manufacturer (or
parenteral/sublingual fentanyl at recommended doses) were used. There was no difference in the use of breakthrough medications
between arms.
Other potential sources of bias
Size of study
A total of 150 (75 ketamine and 75 placebo) evaluable patients were required to provide approximately 85% power to detect an absolute
25% difference in response rate (30% in the placebo group vs 55% in the ketamine group), at a 2-tailed type 1 error of 0.05. The
sample size was reached.
Doses used
The regimen chosen for our study was based on the largest series reported in the literature at the time (Jackson K, Ashby M, Howell
D, et al: The effectiveness and adverse event profile of “burst” ketamine in refractory cancer pain: The VCOG PM 1-00study. J Palliat
Med 14:1074-1077, 2011).
Rapid escalation
Dose escalation only occurred if patients failed to respond after 24 hours of the previous dose as per the largest series reported in
the literature at the time-Opioid doseThe background opioid dose was 300mg OME/day (range 160-480) and 410 (258-700) in the
ketamine and placebo arms respectively.
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Last observation carried forward analysis
The primary analysis was an intention-to-treat (ITT) analysis. The response for participants stopping study drug before day 5 for
reasons unrelated to the intervention was imputed from the last recorded assessment of pain. It is to be noted that the placebo group
achieved the same response rate of analgesics but with much less toxicity.
I do not have any affiliation with or involvement in any organisation with a financial interest in the subject matter of my comment.
Reply
The authors thank Dr. Currow for his feedback regarding the recent update of the Cochrane review entitled “Ketamine as an adjuvant
to opioids for cancer pain”.
Dr. Currow has requested an explanation of why the paper by Hardy et al. was classified as “low level evidence”.
The paper was assessed using the Cochrane Risk of bias tool. The quality of the evidence was assessed using GRADE.
Re. Risk of bias
The paper was judged to have unclear risk of bias as follows:
Detection bias and performance bias
As is evident from the Risk of bias table, we judged this trial to be at unclear risk of bias re. blinding. The detailed information on
blinding that Dr. Currow provides in his email was not included in the published paper which lacks a description of the blinding
procedure.We did however note that the protocol mentioned that “All syringes will look identical in volume and colour”. The trial involved
rapid titration of ketamine to high doses and there was a high rate of adverse events in the ketamine arm. No specific measures were
taken to check for blinding. We judged that it was possible that blinding could therefore have been compromised by psychotomimetic
adverse effects and skin reactions at the needle site, and a check on fidelity to blinding would have helped reduce uncertainty.
Incomplete outcome data (attrition bias)
It is unclear how missing data was imputed. The trial was therefore judged to be at unclear risk of bias due to missing outcome data.
Selective reporting
Assessing “the effect of ketamine on total opioid dose”, which is a relevant outcome of interest was mentioned in the protocol as a
“secondary objective”, but was not reported in the final paper.We judged the study to be at unclear risk of bias due to selective reporting.
Size of study (checking for possible bias confounded by small size)( 1-4).
We assessed studies as being at low risk of bias (200participants or more in each treatment arm); unclear risk of bias (50-199 participants
in each treatment arm; high risk of bias (fewer than 50 participants per treatment arm). We judged the trial by Hardy et al. to be at
unclear risk of bias due to size (50 - 199 participants per treatment arm).
Re. GRADE assessment
For all three studies there was an unclear risk of bias overall. Using GRADE, we judged the quality of the evidence to be very low due
to study limitations and imprecision due to the small number of participants in all comparisons.
We downgraded one level for serious risk of bias and two levels for very serious imprecision due to very small number of participants
in two of the comparisons and small number of participants in the third comparison.
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Re. the ketamine regimen used in the study by Hardy et al.
Dr. Currow writes that the ketamine regimen “was based on the largest series reported in the literature at the time” (5). The dose escalation
was rapid, for example having a start dose of 100 mg/ 24 hours and tripling the dose after less than 20 hours, considering the
pharmacokinetics of ketamine which has a β half-life of two to four hours in humans (6), and where steady state is achieved after five
elimination half-lives. The metabolite norketamine, which is also active has a much longer half-life than ketamine, and very ill cancer
patients would be likely to have a much poorer elimination than young healthy volunteers.
The “burst” ketamine protocol developed by Jackson et al. appears only to have been used by that particular group, and subsequently
by Hardy and colleagues. Mercadante et al. published two reports of cases treated with a “burst” ketamine regimen, but employed a
dose of 100 mg daily for two days, as an adjuvant to opioid (7,8). The ketamine doses and rate of titration in the Hardy trial are higher
than those generally reported and recommended in the cancer pain literature (9). The high rate of adverse events in the ketamine arm
of the trial suggest that “rapid titration involving such doses of continuous subcutaneous infused ketamine is generally inadvisable” (9). The
treatment regimen used in this study cannot be considered representative for ketamine regimens commonly used in palliative care, and
the conclusion that “Ketamine does not have net clinical benefit when used as an adjunct to opioids and standard co-analgesics in cancer
pain” can only apply to this specific, high-dose, rapid titration treatment regimen.
Finally, the basic opioid treatment in the Hardy study was not standardized- participants were treated with different opioids and
different routes of administration. This lack of standardization may have influenced the results.
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Response prepared by the review authors.
Feedback managed by Feedback Editor Hayley Barnes, Managing Editor Anna Erskine, and Senior Editor Andrew Moore.
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Last assessed as up-to-date: 16 December 2016.
Date Event Description
14 August 2017 Feedback has been incorporated See Feedback.
28 June 2017 Review declared as stable See Published notes.
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H I S T O R Y
Protocol first published: Issue 4, 2001
Review first published: Issue 1, 2003
Date Event Description
12 April 2017 New citation required but conclusions have not
changed
We identified one new study with 185 participants (
Hardy 2012). We assessed risk of bias and the quality
of the evidence according to GRADE
12 April 2017 New search has been performed This review has been updated to include the results of
a new search in December 2016/January 2017
13 May 2009 Amended Contact details updated.
30 October 2008 Amended History, What’s New and citation corrected
4 August 2008 Amended Converted to new review format.
19 June 2007 New search has been performed Review updated with revised search but no new trials
were identified for this update
C O N T R I B U T I O N S O F A U T H O R S
RFB: assessed the updated search results for trials for inclusion in the review, undertook quality and validity evaluation of the included
studies, extracted data and wrote the update.
EK: assessed the results of the updated search, undertook quality and validity evaluation of the included studies, and contributed to
the writing of the update.
CE: undertook quality and validity evaluation of the included studies, and contributed to the writing of the update.
D E C L A R A T I O N S O F I N T E R E S T
RFB: none known. RFB is a retired specialist pain physician who has worked with patients having acute, chronic or cancer pain,
including palliative care patients.
CE: none known.
EK: none known. EK is a specialist pain physician who has worked with patients having acute, chronic or cancer pain, including
palliative care patients.
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S O U R C E S O F S U P P O R T
Internal sources
• Regional Centre of Excellence in Palliative Care, Haukeland University Hospital; Centre for Clinical Research, Haukeland
University Hospital, Norway.
For the original review and all updates RF Bell has received funding for a 20% research position
External sources
• Norwegian Research Council, Norway.
For the original review RF Bell received a grant to fund a 30% research position
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We did not search CancerLit as we judged it redundant against current databases. We did not search the PaPaS specialised
register as it is no longer updated. For this update we searched trial registries.
• In this 2017 update, we excluded studies having a group size of fewer than 10 participants who completed the study, and
unpublished studies.
• We excluded studies that were not double-blind. We added the secondary outcomes of total opioid consumption and rescue
medication.
• We also reinstated the secondary outcomes distress and function, which were omitted in previous versions of this review.
• We updated the methods sections to conform to current Cochrane standards. We included ’Risk of bias’ and GRADE
assessments.
• We reported participant withdrawal (dropouts) from the study but no longer narrate it as a secondary outcome but as a feature
of the methods.
• We no longer refer to pain relief as a primary outcome.
N O T E S
A new search within two years is not likely to identify any potentially relevant studies likely to change the conclusions. Therefore,
following discussion with the authors and editors, this review has now been stabilised until 2022, at which point we will assess the review
for updating. If appropriate, we will update the review before this date if new evidence likely to change the conclusions is published,
or if standards change substantially which necessitate major revisions.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Analgesics [adverse effects; ∗therapeutic use]; Chemotherapy, Adjuvant;DrugTherapy, Combination [methods];Hallucinations [chem-
ically induced]; Ketamine [adverse effects; ∗therapeutic use]; Morphine [adverse effects; ∗therapeutic use]; Neoplasms [∗complications];
Pain [∗drug therapy; etiology]; Palliative Care; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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